Pacific Edge Ltd (PEB) reported H2 FY2026 results with significant revenue decline due to loss of Medicare coverage. However, stock rose 5.56% to $0.285.
Net loss after tax was NZD 35.8 million. Cash burn improved in H2, and a successful capital raise was completed.
New generation tests show superior clinical performance. The company aims for profitability in APAC and expanded U.S. market access.
CEO Dr. Peter Meintjes stated: 'Developing next-generation tests is central to our strategy.'
